Tech Company Financing Transactions
CEL-SCI Funding Round
Private investors joined a $10 million funding round for CEL-SCI. The round was announced by the company on 8/29/2025.
Transaction Overview
Company Name
Announced On
8/29/2025
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8229 Boone Blvd
Vienna, VA 22182
USA
Vienna, VA 22182
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geert Kersten
Browse more venture capital transactions:
Prev: 8/29/2025: Munify venture capital transaction
Next: 8/31/2025: MUBI venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs